Prostate cancer decisions — 2024

The Board has remanded the cases for further development and clarification regarding exposure to Agent Orange or other TERA during service, as well as medical opinions on the etiology of the Veteran's skin cancer, right and left lower extremity neuropathy, and tinnitus.

The Veteran's prostate cancer residuals are currently rated as 10 percent disabling. The Board has found no evidence of a GI disorder and remanded the case for further examination to determine if there is service connection or an increased rating for impairment of sphincter control.

The Board has remanded the Veteran's claims for service connection for prostate cancer and thyroid cancer due to a lack of examination and dose assessment, as well as potential TERA exposure. The Veteran is seeking service connection based on his assertions of toxic exposure during active duty.

The Veteran's prostate cancer is rated at 20 percent since September 15, 2020. The Board denied a higher rating as the evidence did not show any recurrence of prostate cancer within the period on appeal.

The Board has remanded the Veteran's claims for service connection for prostate cancer and thyroid cancer due to a lack of examination and dose assessment, as well as potential TERA exposure. The Veteran is seeking service connection based on new evidence.

The Board denied the Veteran's claims of service connection for hypertension and prostate cancer, finding that they did not arise prior to August 10, 2022.

The Veteran's claim for service connection for prostate cancer is readjudicated and granted due to the submission of new and relevant evidence, but the issue remains remanded as further action may be required.

The Veteran's claim for individual unemployability and Dependents' Educational Assistance (DEA) has been granted with effective dates of October 1, 2020.,Previously awarded TDIU from May 16, 2022, the DEA was also retroactively granted to this date.

The Veteran's claims for earlier effective dates for service connection of prostate cancer and diabetes mellitus type II were denied as there was no intent to file or formal claim prior to June 8, 2023.

The Veteran's prostate cancer was diagnosed after the November 2019 rating decision, and the Board is remanding to determine if he was exposed to herbicide agents or toxins in the soil during his service.

The Veteran's prostate cancer residuals are granted an initial 60 percent rating, and his laryngeal cancer (claimed as throat cancer) residuals are granted an initial 10 percent rating.

The Veteran's appeal for prostate cancer and lung disability due to asbestos exposure has been dismissed as the claim was granted in a previous decision. The cervical radiculopathy and cervical spine disability claims are remanded.

The Veteran's claims for service connection for left ear hearing loss and a compensable rating for residuals of prostate cancer from January 1, 2018 are being remanded due to the need for additional medical opinions regarding the etiology of his hearing loss and the severity of his prostate cancer residuals.

The Board has granted the Veteran's claim for service connection for prostate cancer, finding that his exposure to Agent Orange during a period of active duty for training (ACDUTRA) is at least as likely as not related to his current disability. The decision is based on the presumption of herbicide agent exposure.

The Board has dismissed the appeals for special monthly compensation based on service-connected prostate cancer and atherosclerotic cardiovascular disease due to the Veteran's death.

The Veteran's prostate cancer, diabetes mellitus, and diabetic peripheral neuropathy of the upper and lower extremities are granted as service-connected due to presumed exposure to herbicide agents while serving at U-Tapao RTAFB in Thailand.

The Veteran's prostate cancer is granted as presumptive under the PACT Act, and his erectile dysfunction is granted as secondary to his service-connected prostate cancer.,Major depressive disorder is also granted.

The Veteran's prostate cancer was found to be active as of August 4, 2020. However, he had already been receiving a 100% rating since July 26, 2021. The effective date for the 100% rating is set at September 1, 2020.

The Board has granted the Veteran's claim for a total disability rating based on individual unemployability (TDIU) on an extraschedular basis due to his service-connected disabilities, finding that he is unable to secure and follow substantially gainful employment.

The Veteran's claims for prostate cancer, diabetes mellitus type II, and hypertension have been granted. Hypertension is granted based on the PACT Act.,Service connection has also been established for erectile dysfunction as secondary to diabetes mellitus, cataracts as secondary to diabetes mellitus, and chronic kidney disease as secondary to diabetes mellitus.